Get the Stockscreener App
26.59
1.12%
-0.30
Mineralys Therapeutics Inc stock is traded at $26.59, with a volume of 895.38K.
It is down -1.12% in the last 24 hours and up +5.22% over the past month.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
See More
Previous Close:
$26.89
Open:
$26.77
24h Volume:
895.38K
Relative Volume:
0.83
Market Cap:
$2.35B
Revenue:
-
Net Income/Loss:
$-151.78M
P/E Ratio:
-12.91
EPS:
-2.0595
Net Cash Flow:
$-136.42M
1W Performance:
-4.97%
1M Performance:
+5.22%
6M Performance:
+16.22%
1Y Performance:
-31.59%
1-Day Range:
$25.83
$27.07
1-Week Range:
$25.83
$29.83
52-Week Range:
$22.30
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
26.59 | 2.35B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | TD Cowen | Buy |
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Australia
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com Canada
A fund sold Mineralys (MLYS) shares and still holds more than 7.8 million. - Stock Titan
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum - GlobeNewswire
Mineralys to present lorundrostat trial data at AHA meeting By Investing.com - Investing.com Canada
Mineralys to present lorundrostat trial data at AHA meeting - Investing.com India
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 - The Manila Times
Long-term results for a blood pressure drug will be presented at an American Heart Association meeting - Stock Titan
Form 144 Mineralys Therapeutics For: 23 September By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 22 September - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Fund may sell Mineralys (NASDAQ: MLYS) shares; filing shows the size - Stock Titan
(MLYS) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: A Promising 71% Upside Potential In Biotech - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. (MLYS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mineralys Therapeutics (MLYS) officer lines up new stock option sale - Stock Titan
A new employee gets Mineralys stock awards covering 14,880 and 11,160 shares - Stock Titan
Mineralys Therapeutics (MLYS) CCO sells 7,438 shares in pre-set plan - Stock Titan
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Canada
Mineralys Therapeutics director Karydas sells $85,740 in stock - Investing.com
Mineralys Therapeutics (MLYS) director sells shares under preset plan - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) executive plans new stock option sale after recent $388K trade - Stock Titan
Mineralys (NASDAQ: MLYS) officer to sell 3,000 shares via options - Stock Titan
Mineralys Grants Equity Awards to Two New Employees - mychesco.com
Mineralys (MLYS) officer to sell 7,709 shares - Stock Titan
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Mineralys Therapeutics grants inducement equity awards covering 52,080 shares to new hires - Bitget
Mineralys at Wells Fargo conference: lorundrostat launch takes shape By Investing.com - Investing.com Canada
MLYS: Lorundrostat nears approval with strong data, broad market prep, and a focus on parity access - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) insider to sell 2,171 shares via cashless option exercise - Stock Titan
Two new hires get four-year stock awards from Mineralys - Stock Titan
Mineralys Therapeutics Market Sentiment - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Mineralys Therapeutics upgraded to Buy ahead of lorundrostat FDA approval and strong market launch. - Pluang
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS) - Seeking Alpha
Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - Stock Titan
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com Nigeria
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan - Stock Titan
Mineralys (MLYS) Session: Loses 0.39% to Close at $25.65 in Latest Trading; Range Check: the Session Ends Within the Reported Technical BoundariesSkew Index - careplusvn.com
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - Stock Titan
Mineralys Plunges As Costly Royalty Deal Shocks Wall Street - TipRanks
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management - BioBuzz
Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (MLYS) Q2 2026 Earnings Call Transcript - AOL.com
Mineralys Builds $661 Million War Chest Ahead of FDA Decision - MyChesCo
Mineralys Grants Equity Awards to New Medical Chief - MyChesCo
TimesSquare Capital Management LLC Invests $6.36 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE - MarketBeat
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):